New approach prevents thrombosis without increasing the risk of bleeding

Published 2014-02-06 16:06. Updated 2014-02-06 16:09Denna sida på svenska

In collaboration with an international team, researchers at Karolinska Institutet have developed an antibody, 3F7, which blocks a protein that is active in the coagulation system factor XII. Inhibition of factor XII makes it possible to prevent thrombosis in blood vessels without increasing the risk of bleeding in clinical settings.

Thrombosis is caused by blood clotting; clots can block blood flow in one or more blood vessels and so cause thrombotic diseases such as stroke, myocardial infarction or pulmonary embolism. Today, thrombosis is prevented or treated by means of anticoagulants. There is a broad variety of anticoagulant drugs, such as warfarin (a vitamin K inhibitor), the novel oral anticoagulants (dabigatran or rivaroxaban) and drugs of the heparin group. All of these agents target different components of the blood coagulation system to prevent blood from clotting and thus to interfere with thrombosis. However, all these drugs also entail an increased risk of bleeding in patients that partially offsets their beneficial effects.

The blocking of coagulation factor XII (F XII) functions differently compared to traditional anticoagulants. It has been known for long time that humans that are deficient in FXII do not bleed excessively and because of that FXII was believed to have no function for blood coagulation in patients. In 2005, Thomas Renné and his research team discovered that mice lacking F XII could have neither a stroke nor pulmonary embolism, even though they had normal bleeding patterns.

"Since then, our goal has been to find an effective way to block F XII. Now, we have developed an antibody that blocks F XII in human blood, mice and rabbits", says Thomas Renné, professor at the Department of Molecular Medicine and Surgery. "This provides protection against thrombosis without increasing the risk of bleeding."

Together with the doctoral student Magnus Larsson, the researchers developed and tested the antibody, called 3F7, in rabbits during an ECMO treatment. ECMO is an advanced heart-lung machine used in life-threatening conditions especially in infants. Contact with the plastic tubing causes the blood to clot, so patients are routinely administered with anticoagulants (heparin). However due to the heparin anticoagulation patients bleed excessively and a substantial number even dies from these bleedings. In the study, thrombosis in rabbits on ECMO receiving 3F7 decreased was as low as rabbits receiving heparin, but the risk of bleeding with 3F7 was minimal, whereas heparin-treatment led to bleeding.

The study was funded by Swedish Heart-Lung Foundation, Stockholm County Council (ALF), the Swedish Cancer Society, HRH Crown Princess Lovisa's Association for Child Medical Care, the Swedish Research Council, the German Research Society and the European Research Council. Several of those involved in the study are employees of the pharmaceutical company CSL Behring, which has consequently contributed to the study's inception.

Read a press release and find out more about the study


Magnus Larsson, Veronika Rayzman, Msarc W. Nolte, Katrin F. Nickel, Jenny Björkqvist, Anne Jämsä, Matthew P. Hardy, Marion Fries, Stefan Schmidbauer, Patricia Hedenqvist, Michael Broomé, Ingo Pragst, Gerhard Dickneite, Michael J. Wilson, Andrew D. Nash, Con Panousis, and Thomas Renné
A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Extracorporeal Circulation Without Increasing Bleeding Risk
Science Translational Medicine, 5 February 2014, Vol 6 Issue 222 222ra17